Boston Scientific Pauses Watchman FLX Sales In Europe
This article was originally published in The Gray Sheet
Initial rates of device embolizations have convinced the firm to temporarily halt sales of the next-generation FLX left atrial appendage closure device to assess physician training needs. The move, four-and-a-half months after the device was launched on a limited basis in Europe, does not impact sales of the current-generation Watchman system.
Register for our free email digests: